Synonym
Budotitane; CCRIS2873; CCRIS-2873; CCRIS 2873
IUPAC/Chemical Name
Diethoxy-(1-phenyl-1,3-butanedionato)titanium (IV)
InChi Key
HYSIJEPDMLSIQJ-UHFFFAOYSA-N
InChi Code
InChI=1S/2C10H9O2.2C2H5O.Ti/c2*1-8(11)7-10(12)9-5-3-2-4-6-9;2*1-2-3;/h2*2-7H,1H3;2*2H2,1H3;/q4*-1;+4
SMILES Code
CC[O-][Ti+4]12(O=C([CH-]C(c3ccccc3)=O2)C)([O-]CC)O=C([CH-]C(c4ccccc4)=O1)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
460.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Dubler E, Buschmann R, Schmalle HW. Isomer abundance of bis(beta-diketonato) complexes of titanium(IV). Crystal structures of the antitumor compound budotitane [Ti(IV)(bzac)(2)(OEt)(2)] and of its dichloro-derivative [Ti(IV)(bzac)(2)Cl(2)] (bzac=1-phenylbutane-1,3-dionate). J Inorg Biochem. 2003 Jun 1;95(2-3):97-104. doi: 10.1016/s0162-0134(03)00091-6. PMID: 12763653.
2: Tshuva EY, Miller M. Coordination Complexes of Titanium(IV) for Anticancer Therapy. Met Ions Life Sci. 2018 Feb 5;18:/books/9783110470734/9783110470734-014/9783110470734-014.xml. doi: 10.1515/9783110470734-014. PMID: 29394027.
3: Pereira ML, Garcia e Costa F. The blood-testis barrier as a target of some chemotherapeutic agents. Chemotherapy. 2007;53(6):446-8. doi: 10.1159/000110017. Epub 2007 Oct 23. PMID: 17957098.
4: Schilling T, Keppler KB, Heim ME, Niebch G, Dietzfelbinger H, Rastetter J, Hanauske AR. Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane. Invest New Drugs. 1996;13(4):327-32. doi: 10.1007/BF00873139. PMID: 8824351.
5: Caruso F, Rossi M. Antitumor titanium compounds. Mini Rev Med Chem. 2004 Jan;4(1):49-60. doi: 10.2174/1389557043487565. PMID: 14754443.
6: Kaushal R, Kumar N, Thakur A, Nehra K, Awasthi P, Kaushal R, Arora S. Synthesis, Spectral Characterization, Antibacterial and Anticancer Activity of some Titanium Complexes. Anticancer Agents Med Chem. 2018;18(5):739-746. doi: 10.2174/1871520618666171219122431. PMID: 29256358.
7: Keppler BK, Schmähl D. Preclinical evaluation of dichlorobis(1-phenylbutane-1,3-dionato)titanium (IV) and budotitane. Two representatives of the new class of antitumor-active bis-beta-diketonato metal complexes. Arzneimittelforschung. 1986 Dec;36(12):1822-8. PMID: 3566844.
8: Keppler BK, Heim ME, Flechtner H, Wingen F, Pool BL. Assessment of the preclinical activity of budotitane in three different transplantable tumor systems, its lack of mutagenicity, and first results of clinical phase I studies. Arzneimittelforschung. 1989 Jun;39(6):706-9. PMID: 2775338.
9: Köpf-Maier P. Complexes of metals other than platinum as antitumour agents. Eur J Clin Pharmacol. 1994;47(1):1-16. doi: 10.1007/BF00193472. PMID: 7988618.
10: Frühauf S, Zeller WJ. In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors. Cancer Chemother Pharmacol. 1991;27(4):301-7. doi: 10.1007/BF00685116. PMID: 1998986.
